Recent News

• 11.13.2025 - Vaxart Provides Business Update and Reports Third Quarter 2025 Financial Results
• 11.13.2025 - Vaxart Provides Business Update and Reports Third Quarter 2025 Financial Results
• 11.07.2025 - Vaxart to Host Upcoming Conference Calls
• 11.07.2025 - Vaxart to Host Upcoming Conference Calls
• 11.05.2025 - Dynavax Enters Exclusive License Agreement for Vaxart’s Novel Oral COVID-19 Vaccine Program
• 10.20.2025 - Vaxart to Present Research on Second-Generation Norovirus Oral Pill Vaccine Candidate at IDWeek 2025
• 10.08.2025 - Vaxart to Showcase its Norovirus and COVID-19 Oral Pill Vaccine Candidates at World Vaccine Congress Europe 2025
• 09.19.2025 - Vaxart Announces Withdrawal of Reverse Stock Split Proposal
• 09.19.2025 - Vaxart Announces Withdrawal of Reverse Stock Split Proposal
• 09.19.2025 - Vaxart Announces Withdrawal of Reverse Stock Split Proposal

Recent Filings

• 11.13.2025 - 10-Q Quarterly report [Sections 13 or 15(d)]
• 11.13.2025 - EX-99.1 EX-99.1
• 11.13.2025 - 8-K Current report
• 11.05.2025 - 8-K Current report
• 11.05.2025 - 424B5 Prospectus [Rule 424(b)(5)]
• 11.05.2025 - EX-99.1 EX-99.1
• 10.10.2025 - 8-K Current report
• 09.19.2025 - 8-K Current report
• 09.19.2025 - 8-K Current report
• 09.18.2025 - PX14A6G Notice of exempt solicitation submitted by non-management